Somatic changes in primary liver cancer in Russia: A pilot study

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 755, Issue 2, 2013, Pages 90-99

  Kalinina, Olga ^a,b   Marchio, Agnès ^c   Urbanskii, Aleksandr I ^d   Tarkova, Aleksandra B ^d   Rebbani, Khadija ^e   Granov, Dmitri A ^d   Dejean, Anne ^c   Generalov, Mikhail I ^d   Pineau, Pascal ^c  

^a ST PETERSBURG PASTEUR INSTITUTE   (Russian Federation)

^b ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^c INSTITUT PASTEUR   (France)

^d Russian Center for Research in Radiological and Surgical Technologies   (Russian Federation)

^e Institut Pasteur du Maroc   (Morocco)

Author keywords

Chromosomes; Environment; HCC; Liver cancer; Oncogenes; PLC; Tumour suppressors; Viruses

Indexed keywords

AXIN1 PROTEIN; B RAF KINASE; BETA CATENIN; CTNNB1 PROTEIN; K RAS PROTEIN; NFE2L2 PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BILE DUCT CARCINOMA; CANCER RISK; CHROMOSOMAL INSTABILITY; CHROMOSOME 18Q; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENETIC SUSCEPTIBILITY; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; PILOT STUDY; POINT MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; RUSSIAN FEDERATION; SOMATIC MUTATION;

HEPATITIS B VIRUS;

EID: 84881025128     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2013.06.019     Document Type: Article

References (55)

1. Ferlay J., Shin H., Bray F., Forman D., Mathers C., Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet] 2010, International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr/.
2. McGlynn K., London W. Epidemiology and natural history of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 2005, 19:3-23.
3. El-Serag H., Rudolph K. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
4. Wild C., Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009, 286:22-28.
5. Pineau P., Marchio A., Battiston C., Cordina E., Russo A., Terris B., Qin L.-X., Turlin B., Tang Z.-Y., Mazzaferro V., Dejean A. In human hepatocellular carcinoma, chromosome instability depends on p53 status and aflatoxin exposure. Mutat. Res. 2008, 653:6-13.
6. Vineis P., Husgafvel-Pursiainen K. Air pollution and cancer: biomarker studies in human populations. Carcinogenesis 2005, 26:1846-1855.
7. Weinstein I., Joe A. Mechanisms of disease: oncogene addiction a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 2006, 3:448-457.
8. Caraglia M., Giuberti G., Marra M., Addeo R., Montella L., Murolo M., Sperlongano P., Vincenz i.B., Naviglio S., Prete S., Abbruzzese A., Stiuso P. Cell Death Dis. 2011, 2:e150.
9. Prete S., Montella L., Caraglia M., Maiorino L., Cennamo G., Montesarchio V., Piai G., Febbraro A., Tarantino L., Capasso E., Palmieri G., Guarrasi R., Bianco M., Mamone R., Savastano C., Pisano A., Vincenzi B., Sabia A., D'Agostino A., Faiola V., Addeo R. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother. Pharmacol. 2010, 66:837-844.
10. Zaridze D., Brennan P., Boreham J., Boroda A., Karpov R., Lazarev A., Konobeevskaya I., Igitov V., Terechova T., Boffetta P., Peto R. Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet 2009, 373:2201-2214.
11. Shkolnikov V., McKee M., Leon D. Changes in life expectancy in Russia in the mid-1990s. Lancet 2001, 357:917-921.
12. Schecter A., Ryan J., Papke O. Elevated dioxin blood levels in Russian chemical workers and their children following maternal exposure. Chemosphere 1994, 29:2361-2370.
13. Tokarskaya Z., Zhuntova G., Scott B., Khokhryakov V., Belyaeva Z., Vasilenko E., Syrchikov V. Influence of alpha and gamma radiations and non-radiation risk factors on the incidence of malignant liver tumors among Mayak PA workers. Health Phys. 2003, 91:296-310.
14. Pineau P., Meddeb M., Raselli R., Qin L., Terris B., Tang Z., Tiollais P., Mazzaferro V., Dejean A. Effect of TT virus infection on hepatocellular carcinoma development: results of a Euro-Asian survey. J. Infect. Dis. 2000, 181:1138-1142.
15. Kalinina O., Norder H., Vetrov T., Zhdanov K., Barzunova M., Plotnikova V., Mukomolov S., Magnius L. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J. Med. Virol. 2001, 65:517-524.
16. Pineau P., Volinia S., McJunkin K., Marchio A., Battiston C., Terris B., Mazzaferro V., Lowe S., Croce C., Dejean A. MiR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:264-269.
17. Lindh M., Gonzalez J., Norkrans G., Horal P. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. J. Virol. Methods 1998, 72:163-174.
18. Pineau P., Ezzikouri S., Marchio A., Benazzouz M., Cordina E., Afifi R., Elkihal L., Taher Khalfallah M., Mestiri H., Tebbal S., Berkane S., Debzi N., Triki H., Dejean A., Iguer F., Bahri O., Essaid El Feydi A., Benjelloun S. Genomic stability prevails in North-African hepatocellular carcinomas. Dig. Liver Dis. 2007, 39:671-677.
19. Marchio A., Akil A., Terris B., Dejean A., Pineau P. Insertion/deletion polymorphisms are convenient and reliable markers to assess chromosomal instability in human tumors. Int. J. Biol. Markers 2012, 27:e232-e240.
20. Weber J., David D., Heil J., Fan Y., Zhao C., Marth G. Human diallelic insertion/deletion polymorphisms. Am. J. Hum. Genet. 2002, 71:854-862.
21. Lin M., Wei L., Sellers W., Lieberfarb M., Wong W., Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004, 20:1233-1240.
22. Nyblom H., Berggren U., Balldin J., Olsson R. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol. 2004, 39:336-339.
23. Acun T., Terzioǧlu-Kara E., Konu O., Ozturk M., Yakicier M. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma. Mutat. Res. 2010, 684:106-108.
24. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I., Calderaro J., Bioulac-Sage P., Letexier M., Degos F., Clément B., Balabaud C., Chevet E., Laurent A., Couchy G., Letouzé E., Calvo F., Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44:694-698.
25. Li S., Wang H., Li J., Zhang C., Feng Q., Huang P., Yu X., Huang L., Liang Q., Zeng Y. Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J. Hepatol. 2001, 34:840-849.
26. Litviakov N., Denisov E., Takhauov R., Karpov A., Skobel'skaja E., Vasil'eva E., Goncharik O., Ageeva A., Mamonova N., Mezheritskiy S., Sevost'janova N., Koshel A. Association between TP53 gene ARG72PRO polymorphism and chromosome aberrations in human cancers. Mol. Carcinog. 2010, 49:521-524.
27. Stepanov V. Ethnic genomics and hereditary fundamentals of prevalent diseases. J. Russ. Acad. Med. Sci. 2003, 85-88.
28. Revich B., Shaposhnikov D. Temperature-induced excess mortality in Moscow, Russia. Int. J. Biometeorol. 2008, 52:367-374.
29. Onishchenko G., Dement'eva L. Spread of hepatitis virus as a threat to national security. Zh. Mikrobiol. Epidemiol. Immunobiol. 2003, 4:93-99.
30. Ribes J., Clèries R., Esteban L., Moreno M., Bosch F. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J. Hepatol. 2008, 49:233-242.
31. Bulbulyan M., Changuina O., Zaridze D., Astashevsky S., Colin D., Boffetta P. Cancer mortality among Moscow shoe workers exposed to chloroprene (Russia). Cancer Causes Control 1998, 9:381-387.
32. Sokolnikov M., Gilbert E., Preston D., Ron E., Shilnikova N., Khokhryakov V., Vasilenko E., Koshurnikova N. Lung, liver and bone cancer mortality in Mayak workers. Int. J. Cancer 2008, 123:905-911.
33. Onishchenko G., Zhebrun A. Viral hepatitis in Russian Federation. Reference Book 2010, 204. Pasteur Institute, Saint-Petersburg. G. Onishchenko, A. Zhebrun (Eds.).
34. Deterding K., Constantinescu I., Nedelcu F., Gervain J., Nemecek V., Srtunecky O., Vince A., Grgurevic I., Bielawski K., Zalewska M., Bock T., Ambrozaitis A., Stanczak J., Takács M., Chulanov V., Slusarczyk J., Drazd'áková M., Wiegand J., Cornberg M., Manns M., Wedemeyer H. Prevalence of HBV genotypes in Central and Eastern Europe. J. Med. Virol. 2008, 80:1707-1711.
35. Abe K., Hayakawa E., Sminov A., Rossina A., Ding X., Huy T., Sata T., Uchaikin V. Molecular epidemiology of hepatitis B, C, D and E viruses among children in Moscow, Russia. J. Clin. Virol. 2004, 30:57-61.
36. Llovet J., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J., de Oliveira A., Santoro A., Raoul J., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T., Galle P., Seitz J., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., Group S.I.S. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
37. Fleming P., Meyroyan A., Klimova I. Alcohol treatment services in Russia: a worsening crisis. Alcohol Alcohol. 1994, 29:357-362.
38. Favorov M., Fields H., Yashina T., Goldberg E., Yeramishantsev A., Rakchimova H., Burkov A., Margolis H., Lvov D. Hepatitis C virus in the etiology of chronic hepatitis and liver cirrhosis: possibility of mixed viral infections due to parenteral transmission. J. Med. Virol. 1992, 36:184-187.
39. Davila J., Morgan R., Shaib Y., McGlynn K., El-Serag H. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004, 127:1372-1380.
40. Tutelyan V. Deoxynivalenol in cereals in Russia. Toxicol. Lett. 2004, 153:173-179.
41. Dragani T. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol. 2010, 52:252-257.
42. Kondrashova T., Neriish i.K., Ban S., Ivanova T., Krikunova L., Shentereva N., Smirnova I., Zharikova I., Konova M., Taira S., Tsyb A. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim. Biophys. Acta 2006, 1762:59-65.
43. Potekhina E., Lavrov A., Samokhodskaya L., Efimenko A., Balatskiy A., Baev A., Litvinova M., Nikitina L., Shipulin G., Bochkov N., Tkachuk V., Bochkov V. Unique genetic profile of hereditary hemochromatosis in Russians: high frequency of C282Y mutation in population, but not in patients. Blood Cells Mol. Dis. 2005, 35:182-188.
44. Ivanova T., Kondrashova T., Krikunova L., Smirnova I., Shentereva N., Sychenkova N., Rykova E., Zharikova I., Khorokhorina V., Riabchenko N., Zamulaeva I. The polymorphism of catechol-O-methyltransferase (COMT) and hemochromatosis (HFE) genes in the radiocontaminated regions residents with different chromosome aberration frequency. Biophysics 2010, 55:1076-1084.
45. Ma B., Hui E., Mok T. Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol. 2010, 11:75-84.
46. Colombino M., Sperlongano P., Izzo F., Tatangelo F., Botti G., Lombardi A., Accardo M., Tarantino L., Sordelli I., Agresti M., Abbruzzese A., Caraglia M., Palmieri G. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 2012, 3:e259.
47. Hsu H., Jeng Y., Mao T., Chu J., Lai P., Peng S. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am. J. Pathol. 2000, 157:763-770.
48. Kim Y., Park C., Kim H., Choi S., Rew J., Kim D., Koh Y., Jeung K., Lee K., Lee J., Juhng S., Lee J. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008, 23:110-118.
49. Totoki Y., Tatsuno K., Yamamoto S., Arai Y., Hosoda F., Ishikawa S., Tsutsumi S., Sonoda K., Totsuka H., Shirakihara T., Sakamoto H., Wang L., Ojima H., Shimada K., Kosuge T., Okusaka T., Kato K., Kusuda J., Yoshida T., Aburatani H., Shibata T. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Genet. 2011, 43:464-469.
50. Berger A., Pandolfi P. Haplo-insufficiency: a driving force in cancer. J. Pathol. 2011, 223:137-146.
51. Thorgeirsson S., Lee J., Grisham J. Functional genomics of hepatocellular carcinoma. Hepatology 2006, 43:S145-S150.
52. Arnold M., Razum O., Coebergh J. Cancer risk diversity in non-western migrants to Europe: an overview of the literature. Eur. J. Cancer 2010, 46:2647-2659.
53. Royce S., Alsop K., Haydon A., Mead L., Smith L., Tesoriero A., Giles G., Jenkins M., Hopper J., Southey M. The role of SMAD4 in early-onset colorectal cancer. Colorectal Dis. 2010, 12:213-219.
54. Ji G., Wang X., Miao L., Liu Z., Zhang P., Zhang F., Yang J. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma. World J. Gastroenterol. 2006, 12:644-648.
55. Hiwatashi K., Ueno S., Sakoda M., Kubo F., Tateno T., Kurahara H., Mataki Y., Maemura K., Ishigami S., Shinchi H., Natsugoe S. Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma. Ann. Surg. Oncol. 2009, 16:3176-3182.